BioSpace News Archive

For patients battling deadly blood cancers like leukemia or lymphoma or life-threatening blood diseases like sickle cell disease or aplastic anemia, there is a cure.

Axonics Modulation Technologies, Inc., a global medical technology company that has developed and is commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to participate in the virtual Barclays Global Healthcare Conference on March 10, 2021.

Cybin Inc., a biotechnology company focused on progressing psychedelic therapeutics, announced its successful uplisting from the OTC Pink Sheets to the OTCQB® Venture Market.

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange, announced an update on the development of a SARS-CoV-2 vaccine for COVID-19.

Eli Lilly and Company and Incyte announced top-line results from BRAVE-AA2, a Phase 3 study evaluating the efficacy and safety of once-daily baricitinib 2-mg and 4-mg in adults with severe alopecia areata.

Asensus Surgical , Inc. (formerly TransEnterix, Inc.) (NYSE American: TRXC) , a medical device company that is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery™, today announced the Company has received an additional FDA clearance for the Senhance Surgical System

Prelude Therapeutics Inc. (“Prelude”, “the Company”, “we”, “our”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that members of its management team will participate in three upcoming virtual investor conferences: Barclays Global Healthcare Conference Fireside chat at 8:35 a.m. ET on Wednesday, March 10, 2021

- On track to initiate three Phase 1/2 clinical programs in the first half of 2021: PBGM01 for GM1 gangliosidosis (GM1), PBFT02 for frontotemporal dementia with granulin mutations, and PBKR03 for Krabbe disease - - Opened first U.S. site for PBGM01’s Imagine-1 global clinical program and actively recruiting patients; other site activations in progress - - Opening new CMC research and development site to support analytics, assay development, and product testing in 2Q 2021 - -

HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that HOOKIPA’s management team will participate in the upcoming H.C. Wainwright Global Life Sciences Conference held virtually from March 9-10, 2021:

- Mr. Kubik joins Actinium with over 25 years of experience in transformative and award-winning BD and M&A transactions - Proven deal making abilities in the empowered antibody, biologics and gene therapy fields strongly suited to Actinium’s AWE technology platform and Antibody Radiation Conjugates for targeted conditioning